Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market In 2029?
In recent years, the market size for paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) has seen significant growth. The market, which was valued at $5.57 billion in 2024, is projected to rise to $5.97 billion in 2025, yielding a compound annual growth rate (CAGR) of 7.1%. This accelerated growth during the historical period can be ascribed to factors such as an increase in PNH and aHUS cases, elevated investment in research for rare diseases, growing demand for specialized therapies, a rise in awareness about PNH and aHUS, and an increased uptake of complement inhibitors.
The market size for paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) is set to witness considerable expansion in the coming years. It is projected to reach$7.88 billion by 2029″, growing at a compound annual growth rate (CAGR) of 7.2%. Among the potential growth drivers during the forecast period are an increase in regulatory approvals for novel therapies, partnerships between biotech firms and research entities, a surge in demand for custom-made medication, higher investment in start-ups focusing on rare diseases, and an upswing in clinical trials and research endeavors. The forecast period will see significant trends such as strides in complement inhibition treatments, inclusion of gene therapy techniques, evolution in patient-specific medication, advancements in technology-based diagnostic instruments, and integration of technology for distance patient supervision.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24357&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
The growth of the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market is projected to be propelled by the increasing occurrence of rare diseases. These are medical conditions that affect a small fraction of the population, typically less than 200,000 people, and are generally characterized by their complexity, severity, and the requirement for specialized care. Enhanced diagnostic technologies can be credited for the rise in the incidence of such diseases as they allow for better detection and identification of previously underreported or misdiagnosed conditions. PNH and aHUS contribute significantly to our understanding and management of rare diseases by shedding light on their pathophysiology and potential therapeutic targets, particularly for conditions with limited treatment alternatives. As per the data from the Food and Drug Administration, a federal agency based in the US, over 7,000 rare diseases affected more than 30 million people in the US just in November 2024. Consequently, the escalating prevalence of rare diseases is fuelling the expansion of the PNH and aHUS market.
Which Key Market Segments Comprise the Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market and Drive Its Revenue Growth?
The paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)market covered in this report is segmented –
1) By Type: Soliris; Ultomiris
2) By Disease Type: Paroxysmal Nocturnal Hemoglobinuria(PNH); Atypical Hemolytic Uremic Syndrome(aHUS)
3) By Treatment Type: Complement Inhibitors; Plasma Exchange Or Infusion; Other Symptomatic Treatments
4) By Diagnosis Method: Clinical Diagnosis; Genetic Testing; Biomarker Testing
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other Users
Subsegments:
1) By Soliris: Eculizumab For PNH; Eculizumab For aHUS; Eculizumab Biosimilars
2) By Ultomiris: Ravulizumab For PNH; Ravulizumab For aHUS; Ravulizumab Extended-Interval Dosing
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24357&type=smp
Which Areas Are Leading Regions in the Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Expansion Across the Globe?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theParoxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Over the Coming Years?
Dominant entities in the market of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are paying attention to the advancement of innovative offerings such as complement inhibitors, which aim to enhance patient outcomes and convenience. These inhibitors are therapeutic measures used to obstruct certain elements of the complement system, a subsidiary of the immune system that aids in eliminating pathogens and damaged cells. For example, in December 2023, Novartis AG, a pharmaceutical firm based in Switzerland, received approval from the U.S. Food and Drug Administration (FDA) for Fabhalta (iptacopan), the inaugural oral monotherapy for treating adults with paroxysmal nocturnal hemoglobinuria. It offers excellent hemoglobin improvement without necessitating transfusions. This groundbreaking complement inhibitor operates by blocking Factor B in the alternative complement pathway, ensuring extensive control over both intravascular and extravascular hemolysis. Its oral administration enhances disease management and boosts patients’ quality of life by doing away with the problems that come with regular infusions.
View the full report here:
How Is the Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Conceptually Defined?
Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) refer to rare, life-threatening blood disorders caused by uncontrolled activation of the complement system, a part of the immune system. Paroxysmal nocturnal hemoglobinuria (PNH) leads to the destruction of red blood cells, while atypical hemolytic uremic syndrome (aHUS) causes blood clots in small blood vessels, primarily affecting the kidneys and other vital organs.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24357
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model